Bavarian Nordic A/S
CSE:BAVA
Bavarian Nordic A/S
Cash Interest Paid
Bavarian Nordic A/S
Cash Interest Paid Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Interest Paid | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Cash Interest Paid
kr32.2m
|
CAGR 3-Years
10%
|
CAGR 5-Years
11%
|
CAGR 10-Years
23%
|
|
|
Genmab A/S
CSE:GMAB
|
Cash Interest Paid
kr35m
|
CAGR 3-Years
43%
|
CAGR 5-Years
12%
|
CAGR 10-Years
80%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Cash Interest Paid
kr24m
|
CAGR 3-Years
94%
|
CAGR 5-Years
48%
|
CAGR 10-Years
28%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Cash Interest Paid
€15.2m
|
CAGR 3-Years
102%
|
CAGR 5-Years
84%
|
CAGR 10-Years
N/A
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Cash Interest Paid
kr381k
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
13%
|
|
|
Saniona AB
STO:SANION
|
Cash Interest Paid
kr5.9m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
65%
|
CAGR 10-Years
65%
|
|
Bavarian Nordic A/S
Glance View
Bavarian Nordic A/S, established in 1994, is a Danish biotechnology powerhouse distinguishing itself in the development and production of vaccines for infectious diseases and immunotherapies for cancer. The company's journey from a promising start-up to a respected player in the global biotech landscape has been driven by its commitment to innovation and strategic partnerships. Its core operations revolve around a sophisticated platform technology capable of developing vaccines quickly and efficiently. This cutting-edge technology enables Bavarian Nordic to address urgent public health needs, such as growing threats from infectious diseases like smallpox, monkeypox, and Ebola. The company's facility in Kvistgaard is crucial to its operations, allowing it to seamlessly transition from research and development to large-scale production, ensuring a quick response to global health challenges. Revenue generation for Bavarian Nordic is predominantly through contracts and collaborations with governments, health organizations, and pharmaceutical companies. Over the years, the company has secured significant agreements, such as those with the U.S. government for the supply of its smallpox and monkeypox vaccines. These contracts provide a steady income stream, allowing the company to reinvest in its R&D efforts and expand its vaccine pipeline. Moreover, Bavarian Nordic’s strategic acquisitions, like their purchase of Rabipur/RabAvert and Encepur from GlaxoSmithKline, have expanded their portfolio and market presence, providing additional revenue channels. This approach not only sustains the company's growth but also aligns with its long-term vision of addressing unmet medical needs worldwide. By continually leveraging its proprietary technology and expanding its network of strategic collaborations, Bavarian Nordic is well-positioned to advance its mission in the global healthcare arena.
See Also
What is Bavarian Nordic A/S's Cash Interest Paid?
Cash Interest Paid
32.2m
DKK
Based on the financial report for Dec 31, 2024, Bavarian Nordic A/S's Cash Interest Paid amounts to 32.2m DKK.
What is Bavarian Nordic A/S's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 10Y
23%
Over the last year, the Cash Interest Paid growth was -39%. The average annual Cash Interest Paid growth rates for Bavarian Nordic A/S have been 10% over the past three years , 11% over the past five years , and 23% over the past ten years .
You don't have any saved screeners yet